Trial Profile
A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Carotuximab (Primary)
- Indications Choriocarcinoma; Gestational trophoblastic disease
- Focus Therapeutic Use
- Sponsors TRACON Pharmaceuticals
- 07 Nov 2018 Status changed from active, no longer recruiting to discontinued due to rare tumor type, patients eligible via expanded access.
- 10 Sep 2018 Planned End Date changed from 1 Aug 2017 to 1 Dec 2018.
- 10 Sep 2018 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2018.